Charles Schwab’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Charles Schwab’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-17,190	Closed	-$64K	–	3571
2021 Q2	$64K	Sell	17,190 -15,217	-47%	-$50.6K	﹤0.01%	3334
2021 Q1	$113K	Sell	32,407 -8,241	-20%	-$33.4K	﹤0.01%	3373
2020 Q4	$137K	Hold	40,648	–	–	﹤0.01%	3295
2020 Q3	$143K	Hold	40,648	–	–	﹤0.01%	3224
2020 Q2	$187K	Buy	40,648 +3,849	+10%	+$17K	﹤0.01%	3183
2020 Q1	$122K	Hold	36,799	–	–	﹤0.01%	3090
2019 Q4	$225K	Hold	36,799	–	–	﹤0.01%	3021
2019 Q3	$154K	Hold	36,799	–	–	﹤0.01%	3072
2019 Q2	$483K	Buy	+36,799	New	+$451K	﹤0.01%	2827

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Charles Schwab's PHAS Position: Q3 2021 in Review

Charles Schwab sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2021, closing a stake of 17,190 shares — an estimated $64K sold.

Charles Schwab first reported a position in PHAS in Q2 2019 and held it in 9 quarters. The position peaked at $483K in Q2 2019. 61 funds tracked by Wall St. Rank hold PHAS as of Q3 2021.

Charles Schwab reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Charles Schwab sold 17,190 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $64K.
Charles Schwab first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 9 quarters.
Charles Schwab's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $483K in Q2 2019.
61 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.